Koji Itahana

This study identifies that TP53 mutations in AML lead to resistance to VenAza therapy by blocking caspase-3/7 activation after mitochondrial outer membrane permeabilization.

This study identifies BIRC5 as a targetable vulnerability in TP53 mutant AML, showing that survivin/IAP inhibitors can overcome therapy resistance.

This study compares multi-omic profiles of bat and human fibroblasts, revealing differences in mitochondrial function and metabolic stress responses.

This study identifies that TIS-derived extracellular vesicles suppress breast cancer through DKK1-mediated inflammation, contrasting with the pro-tumorigenic effects of the senescence-associated secretome.